Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc., a clinical-stage biopharmaceutical company, has been granted a new U.S. patent for its proprietary deuterated psilocybin analog program, CYB003, designed for the treatment of Major Depressive Disorder (MDD). This patent strengthens Cybin’s intellectual property portfolio, now boasting over 50 granted patents, and is set to provide exclusive rights until at least 2041. The company is gearing up for a Phase 3 trial of CYB003, aiming to commence enrollment by mid-year 2024, as it seeks to address the significant unmet medical needs in mental health care.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
